Cell killing and resistance in pre-operative breast cancer chemotherapy

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Ubezio, Paolo ^a   Cameron, David ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CELL CYCLE; CELL KILLING; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN TISSUE; MATHEMATICAL MODEL; PREOPERATIVE CARE; APOPTOSIS; BIOLOGICAL MODEL; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; PATHOLOGY; TREATMENT OUTCOME; TUMOR REGRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KI-67 ANTIGEN; MODELS, BIOLOGICAL; NEOPLASM REGRESSION, SPONTANEOUS; TREATMENT OUTCOME;

EID: 48949086815     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-201     Document Type: Article

References (37)

1. Tyson JJ Chen K Novak B Network dynamics and cell physiology Nat Rev Mol Cell Biol 2001, 2:908-916 10.1038/35103078 11733770
2. Lupi M Matera G Branduardi D D'Incalci M Ubezio P Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach Cancer Res 2004, 64:2825-2832 10.1158/ 0008-5472.CAN-03-3810 15087399
3. Montalenti F Sena G Cappella P Ubezio P Simulating cancer-cell kinetics after drug treatment: Application to cisplatin on ovarian carcinoma Phys Rev E 1998, 57:5877-5887 10.1103/PhysRevE.57.5877
4. Panetta JC Evans WE Cheok MH Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells Br J Cancer 2006, 94:93-100 10.1038/sj.bjc.6602893 16333308
5. Abbott LH Michor F Mathematical models of targeted cancer therapy Br J Cancer 2006, 95:1136-1141 10.1038/sj.bjc.6603310 17031409
6. Cappuccio A Elishmereni M Agur Z Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model Cancer Res 2006, 66:7293-7300 10.1158/0008-5472.CAN-06-0241 16849579
7. Gardner SN Fernandes M New tools for cancer chemotherapy: Computational assistance for tailoring treatments Mol Cancer Ther 2003, 2:1079-1084 14578473
8. Komarova NL Wodarz D Drug resistance in cancer: Principles of emergence and prevention Proc Natl Acad Sci USA 2005, 102:9714-9719 1172248 15980154 10.1073/pnas.0501870102
9. Kozusko F Bourdeau M Bajzer Z Dingli D A microenvironment based model of antimitotic therapy of Gompertzian tumor growth Bull Math Biol 2007, 69:1691-1708 10.1007/s11538-006-9186-5 17577604
10. Michor F Hughes TP Iwasa Y Branford S Shah NP Sawyers CL Nowak MA Dynamics of chronic myeloid leukaemia Nature 2005, 435:1267-1270 10.1038/ nature03669 15988530
11. Simeoni M Magni P Cammia C De Nicolao G Croci V Pesenti E Germani M Poggesi I Rocchetti M Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents Cancer Res 2004, 64:1094-1101 10.1158/0008-5472.CAN-03-2524 14871843
12. Stamatakos GS Antipas VP Uzunoglu NK Dale RG A four-dimensional computer simulation model of the in vivo response to radiotherapy of glioblastoma multiforme: Studies on the effect of clonogenic cell density Br J Radiol 2006, 79:389-400 10.1259/bjr/30604050 16632619
13. Panetta JC Schaiquevich P Santana VM Stewart CF Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma Clin Cancer Res 2008, 14:318-325 10.1158/1078-0432.CCR-07-1243 18172284
14. Skipper HE Schabel FM Jr Wilcox WS Experimental Evaluation of Potential Anticancer Agents. Xiv. Further Study of Certain Basic Concepts Underlying Chemotherapy of Leukemia Cancer Chemother Rep 1965, 45:5-28 14321918
15. Norton L Simon R The Norton-Simon hypothesis revisited Cancer Treat Rep 1986, 70:163-169 3510732
16. Goldie JH Coldman AJ A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat Rep 1979, 63:1727-1733 526911
17. Cameron DA Gregory WM Bowman A Leonard RC Mathematical modelling of tumour response in primary breast cancer Br J Cancer 1996, 73:1409-1416 8645588
18. Cameron DA Gregory WM Bowman A Anderson ED Levack P Forouhi P Leonard RC Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response Br J Cancer 2000, 83:98-103 10.1054/ bjoc.2000.1216 10883676
19. Komarova NL Wodarz D Effect of Cellular Quiescence on the Success of Targeted CML Therapy PLoS ONE 2007, 2:e990 1991595 17912367 10.1371/ journal.pone.0000990
20. Tindall MJ Please CP Peddie MJ Modelling the formation of necrotic regions in avascular tumours Math Biosci 2008, 211:34-55 10.1016/ j.mbs.2007.09.002 18082225
21. Bertuzzi A Gandolfi A Sinisgalli C Iacoviello D Steel's potential doubling time and its estimation in cell populations affected by nonuniform cell loss Math Biosci 1997, 143:61-89 10.1016/ S0025-5564(97)00002-3 9212594
22. Spinelli L Torricelli A Ubezio P Basse B Modelling the balance between quiescence and cell death in normal and tumour cell populations Math Biosci 2006, 202:349-370 10.1016/j.mbs.2006.03.016 16697424
23. Hayward JL Carbone PP Heuson JC Kumaoka S Segaloff A Rubens RD Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer 1977, 39;1289-1294 10.1002/ 1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F 912660
24. Aitkin M Anderson D Freancis B Hinde J Statistical Modelling in GLIM Oxford Science Publications 1989
25. Kalbfleisch J Probability and Statistical Inference II New York: Springler-Verlag 1979
26. Colozza M Azambuja E Cardoso F Sotiriou C Larsimont D Piccart MJ Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann Oncol 2005, 16:1723-1739 10.1093/annonc/ mdi352 15980158
27. Brown RW Allred CD Clark GM Osborne CK Hilsenbeck SG Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer Clin Cancer Res 1996, 2:585-592 9816207
28. Panetta JC A mathematical model of breast and ovarian cancer treated with paclitaxel Math Biosci 1997, 146:89-113 10.1016/ S0025-5564(97)00077-1 9348741
29. Faneyte IF Schrama JG Peterse JL Remijnse PL Rodenhuis S van de Vijver MJ Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation with outcome Br J Cancer 2003, 88:406-412 10.1038/ sj.bjc.6600749 12569384
30. MacGrogan G Mauriac L Durand M Bonichon F Trojani M de Mascarel I Coindre JM Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi Br J Cancer 1996, 74:1458-1465 8912545
31. Teixeira C Reed JC Pratt MA Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells Cancer Res 1995, 55:3902-3907 7641210
32. Dowsett M Smith IE Ebbs SR Dixon JM Skene A Griffith C Boeddinghaus I Salter J Detre S Hills M Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer Clin Cancer Res 2006, 12:1024s-1030s 10.1158/1078-0432.CCR-05-2127 16467120
33. Miller WR White S Dixon JM Murray J Renshaw L Anderson TJ Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole Br J Cancer 2006, 94:1051-1056 10.1038/ sj.bjc.6603001 16538221
34. Peer PG van Dijck JA Hendriks JH Holland R Verbeek AL Age-dependent growth rate of primary breast cancer Cancer 1993, 71:3547-3551 10.1002/ 1097-0142(19930601)71:11<3547::AID-CNCR2820711114>3.0.CO;2-C 8490903
35. Spratt JS Meyer JS Spratt JA Rates of growth of human neoplasms: Part II J Surg Oncol 1996, 61:68-83 10.1002/ 1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-E 8544465
36. Baguley BC Marshall ES In vitro modelling of human tumour behaviour in drug discovery programmes Eur J Cancer 2004, 40:794-801 10.1016/ j.ejca.2003.12.019 15120035
37. Rew DA Wilson GD Cell production rates in human tissues and tumours and their significance. Part 1: An introduction to the techniques of measurement and their limitations Eur J Surg Oncol 2000, 26;227-238 10.1053/ejso.1999.0781 10753534